Biovica, a company specializing in blood-based cancer monitoring, today announces that it has received the first work order under its recently signed Master Services Agreement with an operating subsidiary of a U.S.-based biotechnology company developing next-generation precision medicines for cancer.
The work order, valued at approximately USD 85,000, covers DiviTum® TKa testing in a First-in-Human Phase 1 study evaluating an oral next-generation CDK inhibitor in patients with advanced solid tumors.
DiviTum TKa will be measured at multiple timepoints during treatment to provide longitudinal information on changes in tumor proliferation as the investigational therapy is evaluated across different dose levels.
The study will initially recruit patients outside the United States, and testing under the work order will be performed at Biovica’s laboratory in Sweden.
“We are pleased to see our new Master Services Agreement translate into a first clinical project. The use of DiviTum TKa across different dose levels is well aligned with the growing role of pharmacodynamic biomarkers in early oncology drug development. This work order is another step in building a scalable Pharma Services business and strengthening our position as a partner to pharmaceutical companies across oncology drug development programs,” said Theis Kipling, CEO of Biovica.